Allogene Therapeutics (ALLO) Cash from Investing Activities (2018 - 2026)

Allogene Therapeutics has reported Cash from Investing Activities for 9 years, with the latest figure at -$29.6 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 579.08% year-over-year to -$29.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.8 million (changed 0.11% YoY) and the FY2025 annual result came in at $95.6 million, up 26.25% from the prior year.
• Cash from Investing Activities declined to -$29.6 million in Q1 2026 per ALLO's latest filing, from $33.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $112.9 million in Q1 2023 and troughed at -$76.0 million in Q3 2024.
• A 5-year average of $24.2 million and a median of $24.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 604.69% in 2023, then plunged 579.08% in 2026.
• Over 5 years, Cash from Investing Activities stood at $49.6 million in 2022, then soared by 36.02% to $67.5 million in 2023, then retreated by 18.57% to $54.9 million in 2024, then plunged by 38.81% to $33.6 million in 2025, then slumped by 188.03% to -$29.6 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$29.6 million, $33.6 million, and $11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.